All enrolled individuals who obtained no less than just one dose of zosuquidar or placebo during induction had been monitored for that incidence of adverse situations (439 clients, 219 on zosuquidar and 210 on placebo). The most typical adverse occasions were relevant to the period of extended and important myelosuppression https://israelntybf.anchor-blog.com/8322632/the-5-second-trick-for-3